How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?
- 7 December 2022
- journal article
- research article
- Published by BMJ in Frontline Gastroenterology
- Vol. 14 (4) , 312-318
Abstract
Objective The second iteration of the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) initiative recommends use of the Simple Endoscopic Score for Crohn’s disease (SES-CD) as a treatment target for patients with CD. We aimed to assess whether the STRIDE-II endoscopic endpoints are achievable and whether the degree of mucosal healing (MH) affects long-term outcomes. Design/method We performed a retrospective observational study between 2015 and 2022. Patients with CD who had baseline and follow-up SES-CD scores after biological therapy initiation were included. The primary outcome was treatment failure, defined as the need for: (1) change of biological therapy for active disease (2) corticosteroid use (3) CD-related hospitalisation or (4) surgery. We compared rates of treatment failure with the degree of MH achieved. Patients were followed up until treatment failure or study end (August 2022). Results 50 patients were included and followed up for median 39.9 (34.6–48.6) months. Baseline characteristics: 62% male, median age 36.4 (27.8–43.9) years, disease distribution (L1: 4, L2: 11, L3: 35, perianal: 18). The proportion of patients achieving STRIDE-II end-points were: SES-CD ≤ 2–25 (50%) and >50% reduction in SES-CD—35 (70%). Failure to achieve SES-CD ≤ 2 (HR 11.62; 95% CI 3.33 to 40.56, p=0.003) or >50% improvement in SES-CD (HR 30.30; 95% CI 6.93 to 132.40, pConclusion Use of SES-CD is feasible in real-world clinical practice. Achieving an SES-CD ≤ 2 or a greater than 50% reduction, as set out by STRIDE-II, is associated with reduced rates of overall treatment failure including CD-related surgery.Keywords
This publication has 17 references indexed in Scilit:
- Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's diseaseGut, 2015
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysisAlimentary Pharmacology & Therapeutics, 2015
- Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONICGastroenterology, 2013
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trialGut, 2013
- Mucosal Healing in Crohnʼs DiseaseInflammatory Bowel Diseases, 2013
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.Gut, 1994
- Clinical, biological, and endoscopic picture of attacks of Crohn's diseaseGastroenterology, 1990
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980